Heranova develops a portfolio of non‑invasive, laboratory‑validated diagnostics for women’s reproductive health, including HerResolve™—a blood‑based test that confirms endometriosis—and a suite of microbiome, receptivity, and ovarian reserve assays that guide fertility treatment. By delivering accurate, cloud‑based results to obstetrician‑gynecologists and fertility clinics, the company enables earlier diagnosis, reduces unnecessary surgeries, and personalizes IVF planning to improve outcomes.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing endometriosis and assessing female fertility often rely on invasive procedures such as laparoscopy or limited hormonal tests, leading to delayed diagnosis, mis‑diagnosis, and suboptimal treatment planning for many women.
Solution
Heranova develops non‑invasive, laboratory‑validated diagnostics that address these gaps. HerResolve™ is a blood‑based test that confirms endometriosis in symptomatic women, enabling earlier and less invasive diagnosis. Complementary assays—including HerEndo™ (vaginal swab microbiome screening), HerBiota™ (uterine microbiome profiling), HerReceptivity™ (NGS‑based endometrial receptivity timing), HerTempo™ (algorithmic ovarian reserve assessment), and HerBiota‑Complete (combined uterine‑vaginal microbiome analysis)—provide clinicians with detailed reproductive health information to personalize fertility treatment and improve IVF outcomes. By integrating these tests into a comprehensive diagnostic workflow, Heranova helps physicians make more informed decisions, reduce unnecessary surgeries, and tailor therapeutic strategies for both endometriosis and infertility.
Target Audience
Primary customers are obstetrician‑gynecologists, reproductive endocrinologists, and fertility clinics seeking accurate, non‑invasive diagnostics for endometriosis and assisted reproduction planning.
Features
- HerResolve™: FDA‑cleared, LDT‑validated blood test that detects biomarkers of endometriosis with high sensitivity and specificity
- HerEndo™: Minimally invasive vaginal swab analyzed by qPCR and NGS to profile the vaginal microbiome associated with early‑stage endometriosis
- HerBiota™ and HerBiota‑Complete: Next‑generation sequencing of uterine (and vaginal) microbiota to identify dysbiosis, chronic endometritis, and guide personalized antimicrobial or probiotic therapy
- HerReceptivity™: NGS‑based assay that determines the optimal window for embryo transfer during IVF, improving implantation rates
- HerTempo™: Proprietary algorithm combining clinical parameters to estimate ovarian reserve and remaining reproductive lifespan
- Cloud‑based reporting platform that delivers encrypted results, trend analytics, and integration-ready PDFs for electronic health record systems